and get StockInvest.us Premium Subscription for FREE
Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Akebia Therapeutics Stock Price (Quote) NASDAQ:AKBA
$0.41 ( 5.14% ) Tuesday, 5th Jul 2022
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $0.30 | $0.51 | Tuesday, 5th Jul 2022 AKBA stock ended at $0.41. This is 5.14% more than the trading day before Friday, 1st Jul 2022. During the day the stock fluctuated 12.58% from a day low at $0.38 to a day high of $0.43. |
| 90 days | $0.30 | $0.60 | |
| 52 weeks | $0.30 | $3.71 |
Historical Akebia Therapeutics prices
| Date | Open | High | Low | Close | Volume |
| 2022-07-05 | $0.39 | $0.43 | $0.38 | $0.41 | 16 216 309 |
| 2022-07-01 | $0.49 | $0.50 | $0.38 | $0.39 | 74 315 155 |
| 2022-06-30 | $0.35 | $0.36 | $0.34 | $0.35 | 24 682 362 |
| 2022-06-29 | $0.46 | $0.51 | $0.36 | $0.38 | 84 320 752 |
| 2022-06-28 | $0.37 | $0.38 | $0.35 | $0.35 | 3 716 188 |
| 2022-06-27 | $0.37 | $0.38 | $0.34 | $0.37 | 5 343 154 |
| 2022-06-24 | $0.40 | $0.41 | $0.36 | $0.37 | 24 016 776 |
| 2022-06-23 | $0.35 | $0.40 | $0.35 | $0.39 | 7 831 990 |
| 2022-06-22 | $0.33 | $0.37 | $0.33 | $0.36 | 7 100 082 |
| 2022-06-21 | $0.35 | $0.36 | $0.32 | $0.35 | 9 162 362 |
| 2022-06-17 | $0.32 | $0.36 | $0.31 | $0.34 | 21 186 574 |
| 2022-06-16 | $0.34 | $0.35 | $0.30 | $0.32 | 18 237 173 |
| 2022-06-15 | $0.39 | $0.40 | $0.33 | $0.35 | 24 566 034 |
| 2022-06-14 | $0.38 | $0.38 | $0.33 | $0.35 | 4 009 232 |
| 2022-06-13 | $0.39 | $0.40 | $0.36 | $0.37 | 6 034 907 |
| 2022-06-10 | $0.42 | $0.43 | $0.39 | $0.41 | 6 104 490 |
| 2022-06-09 | $0.45 | $0.46 | $0.42 | $0.44 | 5 356 145 |
| 2022-06-08 | $0.43 | $0.46 | $0.42 | $0.45 | 6 526 940 |
| 2022-06-07 | $0.37 | $0.44 | $0.37 | $0.43 | 10 546 468 |
| 2022-06-06 | $0.41 | $0.42 | $0.36 | $0.38 | 9 875 577 |
| 2022-06-03 | $0.35 | $0.41 | $0.35 | $0.41 | 7 114 357 |
| 2022-06-02 | $0.35 | $0.36 | $0.33 | $0.36 | 4 614 965 |
| 2022-06-01 | $0.39 | $0.39 | $0.34 | $0.35 | 7 517 395 |
| 2022-05-31 | $0.37 | $0.41 | $0.36 | $0.37 | 9 003 612 |
| 2022-05-27 | $0.34 | $0.37 | $0.33 | $0.37 | 7 984 476 |
| 2022-05-26 | $0.33 | $0.36 | $0.33 | $0.34 | 8 652 389 |
| 2022-05-25 | $0.32 | $0.34 | $0.31 | $0.33 | 5 372 901 |
| 2022-05-24 | $0.32 | $0.33 | $0.30 | $0.32 | 7 303 044 |
| 2022-05-23 | $0.33 | $0.34 | $0.31 | $0.32 | 9 320 406 |
| 2022-05-20 | $0.36 | $0.37 | $0.31 | $0.33 | 11 510 540 |
| 2022-05-19 | $0.34 | $0.37 | $0.32 | $0.35 | 6 913 201 |
| 2022-05-18 | $0.36 | $0.38 | $0.32 | $0.33 | 11 893 265 |
| 2022-05-17 | $0.39 | $0.39 | $0.36 | $0.37 | 9 262 667 |
| 2022-05-16 | $0.36 | $0.39 | $0.35 | $0.38 | 10 619 319 |
| 2022-05-13 | $0.42 | $0.45 | $0.42 | $0.45 | 8 074 676 |
| 2022-05-12 | $0.40 | $0.43 | $0.39 | $0.41 | 9 530 078 |
| 2022-05-11 | $0.41 | $0.45 | $0.40 | $0.42 | 9 752 625 |
| 2022-05-10 | $0.38 | $0.45 | $0.38 | $0.43 | 17 562 885 |
| 2022-05-09 | $0.37 | $0.39 | $0.35 | $0.35 | 9 344 550 |
| 2022-05-06 | $0.40 | $0.42 | $0.38 | $0.38 | 8 451 649 |
| 2022-05-05 | $0.42 | $0.44 | $0.41 | $0.41 | 7 310 325 |
| 2022-05-04 | $0.43 | $0.44 | $0.40 | $0.44 | 6 438 522 |
| 2022-05-03 | $0.42 | $0.45 | $0.42 | $0.43 | 7 597 120 |
| 2022-05-02 | $0.41 | $0.43 | $0.40 | $0.43 | 11 050 696 |
| 2022-04-29 | $0.42 | $0.44 | $0.41 | $0.42 | 6 298 479 |
| 2022-04-28 | $0.42 | $0.44 | $0.40 | $0.42 | 8 279 311 |
| 2022-04-27 | $0.45 | $0.47 | $0.42 | $0.43 | 10 632 440 |
| 2022-04-26 | $0.47 | $0.47 | $0.44 | $0.45 | 8 460 635 |
| 2022-04-25 | $0.47 | $0.48 | $0.45 | $0.47 | 8 448 804 |
| 2022-04-22 | $0.48 | $0.50 | $0.46 | $0.48 | 4 995 420 |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is ... ![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
